• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Zymeworks Inc.

Member Profile

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers.

Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Antibodies
  • Bioprocessing
  • Drug Discovery
  • Immune Therapy
  • Oncology
  • Product Development
  • Therapeutics
This member is looking for Business Development
Company Stage Clinical Stage, Discovery Preclinical studies , Phase 1 clinical studies, Phase 2 clinical studies , Phase 3 clinical studies, Public Company
Employees outside Canada 100+ employees
Stock Ticker ZYME - NYSE

Member Profile

Biotechnology, Therapeutics

Zymeworks Inc.

Silver Sponsor

  • Website www.zymeworks.com
  • Phone +1 (604) 678 1388
  • Email info@zymeworks.com
  • Address
    800 - 114 East Fourth Avenue
    Vancouver, BC
    V5T 1G4
  • Leadership Contact
    Ali Tehrani, President & CEO
    Follow us:
  • Twitter
  • LinkedIn
  • News
  • Jobs

March 14, 2023

Zymeworks to Present Updated Data on Multiple Product Candidates at The American Association for Cancer Research (AACR) Annual Meeting

January 19, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months From Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

December 9, 2022

New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented at 2022 SABCS

November 8, 2021

Zymeworks to Present at Upcoming Investor Conferences

August 3, 2021

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms

March 9, 2023

Scientist, In Vivo Biology & PK

March 9, 2023

Research Associate II, Analytics (Mass Spectrometry)

March 9, 2023

Scientist, DMPK/ADME

March 9, 2023

Scientist, In Vitro Pharmacology

March 9, 2023

Senior Research Associate, In Vitro Pharmacology
  • Twitter
  • Linkedin
Tweets by Zymeworks Inc.
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us